论文部分内容阅读
BACKGROUND:In this phase II trial,we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas(MGs).METHODS:Eligible patients received daily temozolomide(50 mg/m2)continuously until progression.The primary endpoint was progression-free survival rate at 6 months in the glioblastoma cohort(N=37).In an exploratory analysis,10 additional recurrent grade III MG patients were enrolled.Correlative studies included evaluation of 76 frequent mutations in glioblastoma(iPLEX assay,Sequenom)aiming at establishing the frequency of potentially“drugable”mutations in patients entering
BACKGROUND: In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs). METHODS: Eligible patients received daily temozolomide (50 mg / m2) -free survival rate at 6 months in the glioblastoma cohort (N = 37) .In an exploratory analysis, 10 additional recurrent grade III MG patients were enrolled. Correlative studies included evaluation of 76 frequent mutations in glioblastoma (iPLEX assay, Sequenom) aiming at establishing the frequency of potentially “drugable” mutations in patients entering